JAZZ PHARMACEUTICALS, INC. for JAZZ PHARMACEUTICALS, INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 18, 2025 | $520,000 | Replaced |
| 4th Quarter - Amendment | Jan 21, 2025 | $540,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S. 2860 - SAFER Banking Act HR 5539/ S. 3131 - Orphan Cures Act HR 8467 - Farm, Food, and National Security Act of 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for Fiscal Year 2025 Control status of Epidiolex Changes to Inflation Reduction Act Drug safety, prescription drug abuse, value of prescription drugs Issues related to the regulation of cannabis and CBD Research and development of cannabis-derived therapies
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK BOLTON | — |
| KARAS GROSS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.